New Triple-Drug cocktail shows promise for tough lung cancers
NCT ID NCT04791839
First seen Nov 05, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests a combination of three drugs (zimberelimab, domvanalimab, and etrumadenant) in 30 adults with advanced non-small cell lung cancer who have already tried immunotherapy. The goal is to see if the triple therapy can shrink tumors or slow cancer growth. Researchers are also monitoring side effects and how long patients stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.